Lei Li
Impact in
- Oncology top 2%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- HER2/EGFR in Cancer Research
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
Papers in
- Oncology 92
- Cancer Cells and Metastasis 21
- Pancreatic and Hepatic Oncology Research 11
- Peptidase Inhibition and Analysis 11
- Lung Cancer Research Studies 9
-
- Epigenetics and DNA Methylation 20
- Cancer-related gene regulation 11
- RNA modifications and cancer 10
- Co-authors
- Xin‐Yuan Guan (27 shared papers)Weiya Xia (2 shared papers)Mien‐Chie Hung (2 shared papers)Ruth L. Katz (2 shared papers)Chawnshang Chang (3 shared papers)Wen‐Jye Lin (2 shared papers)Tingting Zeng (14 shared papers)Kouji Izumi (2 shared papers)
- Journals
- Oncogene (5 papers)Biomedicine & Pharmacotherapy (4 papers)Cancer Research (4 papers)Leukemia (3 papers)Cell Death and Disease (3 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Lei Li
141 papers receiving 3.7k citations
Peers
Comparison fields: 5 of 139
- Oncology 1.5k
- Cancer Research 764
- Immunology 530
- Molecular Biology 1.7k
- Otorhinolaryngology 89
Countries citing papers authored by Lei Li
This map shows the geographic impact of Lei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lei Li more than expected).
Fields of papers citing papers by Lei Li
This network shows the impact of papers produced by Lei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lei Li. The network helps show where Lei Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Lei Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 147 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 289 | |
| 2 | Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. | 1999 | 246 |
| 3 | 2013 | 200 | |
| 4 | Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. | 1997 | 127 |
| 5 | 2021 | 123 | |
| 6 | 2018 | 112 | |
| 7 | 2012 | 104 | |
| 8 | 2014 | 75 | |
| 9 | 2020 | 72 | |
| 10 | 2012 | 70 | |
| 11 | 2018 | 70 | |
| 12 | 2018 | 70 | |
| 13 | 2013 | 68 | |
| 14 | 2022 | 68 | |
| 15 | 2016 | 66 | |
| 16 | 2021 | 66 | |
| 17 | 2012 | 59 | |
| 18 | 2020 | 55 | |
| 19 | 2015 | 51 | |
| 20 | 2009 | 51 |
About Lei Li
Lei Li is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Surgery, having authored 147 papers that have together received 3.8k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (21 papers), Epigenetics and DNA Methylation (20 papers), Cancer, Hypoxia, and Metabolism (13 papers), Pancreatic and Hepatic Oncology Research (11 papers), Cancer-related gene regulation (11 papers), Peptidase Inhibition and Analysis (11 papers), RNA modifications and cancer (10 papers) and Lung Cancer Research Studies (9 papers). The work is most often cited by research in Oncology (1.5k citations), Cancer Research (764 citations), Immunology (530 citations), Molecular Biology (1.7k citations) and Otorhinolaryngology (89 citations). Lei Li has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Xin‐Yuan Guan, Weiya Xia, Mien‐Chie Hung, Ruth L. Katz, Chawnshang Chang, Wen‐Jye Lin, Tingting Zeng, Kouji Izumi, Lei‐Ya Fang and Atsushi Mizokami. Their work appears in journals such as Oncogene, Biomedicine & Pharmacotherapy, Cancer Research, Leukemia and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.